Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

By Peter M. Rothwell, Gerald R Fowkes, J. Belch, H. Ogawa, C. Warlow, T. Meade. The Lancet, 2011

1,468 citations recorded by the source corpus.

Subfields: Cancer Research, Pharmacology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/666e33786caedcbacb72a29fcdd070877794e9a6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Karin
2. A. Mantovani
3. S. Grivennikov
4. Lisa M. Coussens
5. F. Greten
6. F. Balkwill
7. Y. Ben‐Neriah
8. C. López‐Otín

In Pharmacology

1. M. Karin
2. Guido Kroemer
3. Linda Partridge
4. F. Balkwill
5. Beth Levine

In Psychiatry and Mental health

1. M. Karin
2. Lisa M. Coussens
3. A. Mantovani
4. F. Balkwill
5. F. Greten
6. J. Pollard

Citations in the corpus

• Cancer-related inflammation: common themes and therapeutic opportunities. (2012, background): “A recent study of particular interest was an analysis of deaths due to cancer in a cohort of patients randomized to receive aspirin or placebo in trials originally planned to study prevention of vascular disease [90].”
• Inflammation meets cancer, with NF-κB as the matchmaker (2011, background): “Daily aspirin use at doses as low as 75 mg per day for 5 years or longer has been found to diminish death due to several common cancers, with 55–75% lower risk of death for the main types of cancer, such as colorectal, pancreatic and lung carcinoma”
• Differential Macrophage Programming in the Tumor Microenvironment (2012, positive): “The importance of PGE2 in cancer is inferred from the preventative effects of cyclooxygenase-2 (COX-2) inhibitors including aspirin in colon [108, 109] and respective transgenic mouse models [108], as well as a less prominent effect in multiple other cancers [110].”
• Inflammation and Cancer: Triggers, Mechanisms and Consequences (2019, background): “These evidences include large clinical studies on “non-specific” inhibition of inflammation with non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, reducing incidence and mortality in many cancers (Rothwell et al., 2011; Rothwell et al., 2012); or specific inhibition of cytokines such a”
• Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention (2014, result): “These estimates were, however, based on 36 gastric cancer deaths only (87).”
• Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. (2013, background): “…administration of nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin can be tumor preventive and significantly reduce incidence of many solid tumor entities, including colorectal cancer (Rothwell et al., 2011), suggesting a specific effect of low-grade inflammation in this context.”
• The hallmarks of aging. (2013, background): “Moreover, the long-term administration of anti-inflammatory agents such as aspirin may increase longevity in mice and healthy aging in humans (Rothwell et al., 2011; Strong et al., 2008).”